Insulin pump manufacturer Medtronic has announced that the MiniMed 780G, its latest ‘hybrid closed loop’ system for personal type 1 diabetes management, has been approved for sale in Europe.
Medtronic plans to start rolling out this new device to a number of European countries this autumn. But when it will be therefore available to buy in the UK remains unclear – and NHS provision is likely to be a slow process.
The MiniMed 780G is Medtronic’s second hybrid closed loop system, the first one being the MiniMed 670G, which launched in the UK last year.
The new system has some features that previous models did not have, aiming to make type 1 management simpler, including correction boluses, customisable blood glucose targets, reduced alarms, a simplified interface and Bluetooth connectivity.
The MiniMed 780G has been approved to be sold in Europe for those aged 7-80.
Low levels of UK access to type 1 diabetes technology
JDRF’s recent Pathway to Choice report showed that access to diabetes technology in the UK was low, with CGM not having mandated funding on the NHS, and pump uptake stagnating at around 15% in adults and 32% in children and young people in England and Wales according to the most recent National Diabetes Audit.
JDRF and partners will continue to push for access to type 1 diabetes technology for those who want and need it on the NHS.
Read about JDRF’s Pathway to Choice campaign.